Click on the "Follow" button below and you'll get the latest news from Femtechinsiderfeed via email, mobile or you can read them on your personal news page on this site.
You can unsubscribe anytime you want easily.
You can also choose the topics or keywords that you're interested in, so you receive only what you want.
Femtechinsiderfeed title: Homepage - Femtech Insider
Is this your feed? Claim it!
Chinese femtech startup Micro Inno (微新医疗), a Hangzhou-based provider of intelligent solutions for women’s health, has raised eight-figure RMB (multi-million USD) in Series A+ round funding. The round was co-led by Chuanggu Capital, Hefei Industry Investment, and Guoyuan Equity. The new funds will be used to build a medical device platform for women’s health and to accelerate ...
GE HealthCare has received FDA Premarket Authorization for Pristina Recon DL, a deep learning-based image reconstruction technology for 3D mammography. The technology uses artificial intelligence to deliver sharper images with fewer artifacts and enhanced details. Pristina Recon DL is an enhancement to GE HealthCare’s Pristina Via system and is the first mammography technolog...
Three organizations have recently opened applications for grants totaling over $1.3 million to support women’s health research, reproductive medicine projects, and AI-driven solutions addressing challenges faced by women globally. American Heart Association: $1M for Women’s Health Research The American Heart Association has opened applications for its Redefining Women’s Healt...
US Fertility has formed a partnership with L Catterton, which is joining as a new co-lead investor alongside existing backer Amulet Capital Partners. Under the ownership restructuring, L Catterton and Amulet will serve as co-lead investors, while US Fertility’s physician partners will continue to hold substantial ownership. Amulet is increasing its investment and will remain ...
The US Food and Drug Administration has approved POHERDY (pertuzumab-dpzb), developed by Henlius and commercialized by Organon, as the first biosimilar to PERJETA (pertuzumab) in the United States. The approval covers all indications of the reference product for treating HER2-positive breast cancer. POHERDY is approved as an interchangeable biosimilar for use in combination w...
